47,393 Artivion, Inc. $AORT Shares Sold by Sterling Capital Management LLC

Key Points

• Sterling Capital Management cut its Artivion stake by 96.9% in the third quarter, selling 47,393 shares and retaining 1,513 shares worth about $35,000. Institutional investors and hedge funds collectively own 86.37% of the stock.
• Artivion reported quarterly revenue of $123.8 million, above analyst estimates, and EPS of $0.08 versus a consensus estimate of a $0.06 loss. However, the article also notes a $7.9 million GAAP net loss and an 8% year-over-year decline in adjusted EBITDA.
• The company forecast 2026 revenue of $484 million to $492 million and is preparing a January 2027 launch of its NEXUS product. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $42.86.

Sterling Capital Management LLC trimmed its position in Artivion, Inc. (NYSE:AORT - Free Report) by 96.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,513 shares of the company's stock after selling 47,393 shares during the period. Sterling Capital Management LLC's holdings in Artivion were worth $35,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of AORT. BlackRock Inc. bought a new position in shares of Artivion during the second quarter worth about $149,965,000. Dimensional Fund Advisors LP lifted its stake in Artivion by 4.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,027,575 shares of the company's stock valued at $37,626,000 after acquiring an additional 46,738 shares in the last quarter. Wellington Management Group LLP lifted its stake in Artivion by 9.0% in the 2nd quarter. Wellington Management Group LLP now owns 1,260,279 shares of the company's stock valued at $28,318,000 after acquiring an additional 103,592 shares in the last quarter. Bank of America Corp DE lifted its stake in Artivion by 0.8% in the 1st quarter. Bank of America Corp DE now owns 522,515 shares of the company's stock valued at $19,135,000 after acquiring an additional 3,980 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Artivion by 8.7% in the 1st quarter. Principal Financial Group Inc. now owns 261,370 shares of the company's stock valued at $9,571,000 after acquiring an additional 20,921 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Price Performance

NYSE:AORT opened at $25.06 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The stock's 50-day simple moving average is $23.67 and its 200 day simple moving average is $29.09. The company has a market cap of $1.22 billion, a P/E ratio of -357.89 and a beta of 1.31. Artivion, Inc. has a 52-week low of $19.16 and a 52-week high of $48.25.

Artivion (NYSE:AORT - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.14. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. The business had revenue of $123.79 million for the quarter, compared to analyst estimates of $120.97 million. As a group, sell-side analysts forecast that Artivion, Inc. will post 0.45 EPS for the current fiscal year.

More Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Revenue rose 9% year over year to $123.8 million, exceeding analyst expectations of about $121 million. Artivion Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Artivion forecast 2026 revenue of $484 million to $492 million and said it is preparing to launch its NEXUS product in January 2027, offering potential growth catalysts. Artivion outlines 2026 revenue and NEXUS launch
• Negative Sentiment: Artivion reported a GAAP net loss of $7.9 million, or $0.16 per diluted share. Non-GAAP EPS was $0.08, down from $0.16 a year earlier and below Zacks’ $0.11 consensus estimate—despite other reports citing a lower consensus benchmark. Artivion lags Q3 earnings estimates
• Negative Sentiment: Adjusted EBITDA fell 8% year over year to $22.5 million, tempering the positive revenue growth. Artivion Reports Third Quarter 2026 Financial Results

Insiders Place Their Bets

In other news, CEO James Mackin sold 70,000 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the sale, the chief executive officer owned 877,275 shares in the company, valued at $25,397,111.25. This represents a 7.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Jean Holloway sold 977 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the sale, the senior vice president owned 184,118 shares in the company, valued at approximately $5,245,521.82. This represents a 0.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 90,460 shares of company stock valued at $2,557,366 in the last 90 days. 6.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AORT. Needham & Company LLC reaffirmed a "buy" rating and set a $44.00 price target on shares of Artivion in a research note on Monday, July 20th. Jefferies Financial Group assumed coverage on shares of Artivion in a report on Tuesday, October 20th. They issued a "buy" rating and a $31.00 price objective on the stock. Wall Street Zen lowered shares of Artivion from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Canaccord Genuity Group increased their target price on shares of Artivion from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Tuesday, August 18th. Finally, Citigroup restated a "market outperform" rating on shares of Artivion in a report on Tuesday, July 21st. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $42.86.

About Artivion

Artivion, Inc NYSE: AORT is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company's products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.